Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 1,195 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 1,195 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $27.00, for a total value of $32,265.00. Following the transaction, the insider directly owned 395,794 shares of the company’s stock, valued at $10,686,438. This represents a 0.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Monday, August 10th, Susan Bobulsky sold 3,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00.
• On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.00, for a total transaction of $31,176.00.
• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total transaction of $10,714.00.

Adaptive Biotechnologies Stock Up 3.2%

ADPT traded up $0.88 during midday trading on Thursday, reaching $28.55. The company’s stock had a trading volume of 3,279,633 shares, compared to its average volume of 2,297,749. The firm has a market capitalization of $4.56 billion, a price-to-earnings ratio of -69.63 and a beta of 2.09. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $28.72. The stock’s 50-day moving average is $24.08 and its 200-day moving average is $18.49.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 21.5% on a year-over-year basis. As a group, research analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at $28,000. Nykredit A S bought a new position in Adaptive Biotechnologies during the 2nd quarter valued at about $31,000. Allworth Financial LP bought a new position in Adaptive Biotechnologies during the 2nd quarter valued at about $35,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the last quarter. Finally, KBC Group NV purchased a new stake in shares of Adaptive Biotechnologies during the 1st quarter valued at about $45,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. TD Cowen lifted their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Morgan Stanley upped their price target on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Guggenheim raised their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corp. (NASDAQ: ADPT) is a biotechnology company focused on applying immune-system data to the diagnosis and treatment of disease. The company develops technologies that decode T-cell and B-cell receptors, helping researchers and clinicians analyze the adaptive immune response at the scale of individual immune cells.

Its key products include clonoSEQ, a clinical diagnostic test that measures minimal residual disease in certain blood cancers, including multiple myeloma and acute lymphoblastic leukemia.